Yaffa Shir-Raz, addresses claims made against her article regarding safety concerns for RSV monoclonal antibodies. The focus of her response is on the evidence surrounding the approval and review process of these products, particularly the role of the FDA and the Advisory Committee on Immunization Practices (ACIP).
1. Importance of Safety Data:
• Presenting complete safety records, including all related deaths, is crucial. The FDA did not present Merck’s clesrovimab to an advisory committee, instead relying solely on ACIP for review. This limited oversight heightens the need for transparency regarding safety data.
2. Clarification of Arguments:
• The critique includes personal attacks which detract from a scientific dialogue and are not addressed further.
• Disagreements about the presentation of risk between age groups in clinical studies are clarified. Shir-Raz argues that a combined analysis revealing increased seizure risk was not presented adequately to ACIP.
3. Claims of Different Products:
• The critic asserts that clesrovimab and nirsevimab are fundamentally different, which contradicts FDA's classification of them as similar products. This distinction should have warranted independent safety reviews.
4. Transparency in Mortality Data:
• There are claims that deaths during trials were reviewed and found unrelated, which Shir-Raz contests by highlighting discrepancies in how information was presented to ACIP. The absence of complete narratives surrounding mortality instances prevents proper assessment of safety signals.
5. Need for Full Disclosure:
• Regulatory standards require detailed reporting of any deaths or serious adverse events in clinical trials. The lack of detailed mortality data obstructs transparent scrutiny from advisory committees and the public.
6. Methodological Issues:
• Criticism of dismissing mortality signals from varied causes ignores pharmacovigilance principles, which recognize patterns across different types of outcomes. The author stresses the importance of population-level mortality signals over individual case assessments.
7. Real-World Data and Effectiveness Comments:
• Questions about effectiveness figures cited by the critic are raised. Shir-Raz points out that hospitalizations, while important, should not overshadow mortality as a critical endpoint in assessing the safety and effectiveness of a new treatment.
8. Concerns Over Data Quality:
• Reports of effectiveness based on weak observational studies are scrutinized for credibility, as they are not subjected to the same rigorous standards as peer-reviewed regulatory documents.
Shir-Raz concludes that the discourse surrounding the safety of RSV monoclonal antibodies must prioritize transparency. The emerging mortality imbalance in trials for products intended for healthy infants necessitates complete and detailed data to inform both advisory committees and the public. This ensures that safeguards for infant safety remain strong and scientifically grounded. The focus on protecting infants and addressing emerging safety signals should guide the ongoing discussion and review process.
No comments:
Post a Comment